TLX trades 70.6% below Wall Street's consensus target of $18.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLX achieves its forward estimates and maintains a stable P/E multiple of 88.9x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Telix Pharmaceuticals Limited (TLX) has a Wall Street consensus price target of $18.00, based on estimates from 5 covering analysts. With the stock currently trading at $10.55, this represents a potential upside of +70.6%. The company has a market capitalization of $3.57B.
Analyst price targets range from a low of $18.00 to a high of $18.00, representing a 0% spread in expectations. The median target of $18.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TLX trades at a trailing P/E of -480.2x and forward P/E of 88.9x. Analysts expect EPS to grow -49.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.49, with bear and bull scenarios of $12.91 and $27.00 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXELExelixis, Inc. | $14.7B | $58.39 | $51.78 | -11.3% | Hold | 16.6x | 33 |
 RNWReNew Energy Global Plc | $2.5B | $6.84 | $7.02 | +2.6% | Buy | 0.5x | 6 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.96 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 NVSNovartis AG | $268.0B | $141.00 | $136.00 | -3.5% | Hold | 16.0x | 25 |
 BMYBristol-Myers Squibb Company | $124.9B | $61.15 | $69.22 | +13.2% | Buy | 8.8x | 42 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $295.51 | $603.83 | +104.3% | Buy | — | 18 |
 GEGE Aerospace | $321.2B | $309.56 | $409.60 | +32.3% | Buy | 39.1x | 35 |
 GEHCGE HealthCare Technologies Inc. | $29.0B | $64.29 | $79.92 | +24.3% | Buy | 13.1x | 18 |
 SYKStryker Corporation | $105.6B | $275.43 | $370.16 | +34.4% | Buy | 18.4x | 52 |
Quick answers to the most common questions about buying TLX stock.
The consensus Wall Street price target for TLX is $18, representing 70.6% upside from the current price of $10.55. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TLX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $18 implies 70.6% upside from current levels.
At a forward P/E of 88.8795x, TLX trades at a premium valuation. The consensus price target of $18 (70.6% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $18 for TLX, while the most conservative target is $18. The consensus of $18 represents the median expectation. Our quantitative valuation model projects a bull case target of $27 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TLX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLX stock forecast based on 5 Wall Street analysts shows a consensus price target of $18, with estimates ranging from $18 (bear case) to $18 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $13/$27.
Our quantitative valuation model calculates TLX's fair value at $20 (base case), with a bear case of $13 and bull case of $27. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
TLX trades at a forward P/E ratio of 88.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TLX, with a "Buy" consensus rating and $18 price target (70.6% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLX analyst price targets range from $18 to $18, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18 consensus represents the middle ground. Our model's $13-$27 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.